{"denoms":[{"counts":[{"groupId":"BG000","value":"598"},{"groupId":"BG001","value":"602"},{"groupId":"BG002","value":"1200"}],"units":"Participants"}],"groups":[{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"BG000","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"BG001","title":"Cabazitaxel 25 mg/m^2"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"182"},{"groupId":"BG001","value":"180"},{"groupId":"BG002","value":"362"}]}],"title":"<65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"296"},{"groupId":"BG001","value":"295"},{"groupId":"BG002","value":"591"}]}],"title":"65 to 74 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"120"},{"groupId":"BG001","value":"127"},{"groupId":"BG002","value":"247"}]}],"title":"≥75 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"598"},{"groupId":"BG001","value":"602"},{"groupId":"BG002","value":"1200"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}